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A 23-year-old woman with known polycystic ovary syndrome visits her family physi-
cian. She has taken oral contraceptive pills in the past but did not tolerate them and is 
not currently receiving any treatment. She has three or four menstrual periods per 
year and is not interested in becoming pregnant now, but she will be getting married 
in a year. She has heard that the polycystic ovary syndrome is associated with diabetes 
and is concerned because both her mother and father have type 2 diabetes. Her body-
mass index (the weight in kilograms divided by the square of the height in meters) is 
32, her waist circumference is 38 in. (96.5 cm), her serum total testosterone level is 
elevated at 0.9 ng per milliliter (90 ng per deciliter, or 2.9 nmol per liter), her plasma 
high-density lipoprotein cholesterol level is 35 mg per deciliter (0.9 mmol per liter), 
and her triglyceride level is 190 mg per deciliter (2.1 mmol per liter). Her serum 
glucose level 2 hours after the ingestion of 75 g of dextrose is 138 mg per deciliter 
(7.7 mmol per liter). The physician wonders whether treatment with metformin 
would be beneficial and refers the patient to an endocrinologist.
The Cl inic a l Problem
The polycystic ovary syndrome is a clinical diagnosis characterized by the presence 
of two or more of the following features: chronic oligo-ovulation or anovulation, 
androgen excess, and polycystic ovaries.1 It affects 5 to 10% of women of childbear-
ing age2,3 and is the most common cause of anovulatory infertility in developed 
countries. Common clinical manifestations include menstrual irregularities and 
signs of androgen excess such as hirsutism, acne, and alopecia.
The polycystic ovary syndrome is associated with important metabolic derange-
ments. The prevalence of type 2 diabetes in the United States is 10 times as high 
among young women with the polycystic ovary syndrome as among normal 
women,4,5 and impaired glucose tolerance or overt type 2 diabetes develops by the 
age of 30 years in 30 to 50% of obese women with the polycystic ovary syndrome.4‑6 
The prevalence of the metabolic syndrome is two to three times as high among 
women with the polycystic ovary syndrome as among normal women matched for 
age and body-mass index, and 20% of women with the polycystic ovary syndrome 
who are younger than 20 years of age have the metabolic syndrome.7 Although 
outcome data specifically for women with the polycystic ovary syndrome are lack-
ing, the risk of fatal myocardial infarction is twice as high among women with 
severe oligomenorrhea, most of whom would be expected to have the polycystic 
ovary syndrome, as among women with eumenorrhea.8
This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion 
of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, 
the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines,  
if they exist, are presented. The article ends with the author’s clinical recommendations. 
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Pathoph ysiol o gy a nd Effec t  
of Ther a py
The pathophysiological characteristics of the poly-
cystic ovary syndrome are not fully understood 
but are known to involve complex interactions be-
tween the actions of gonadotropins, the ovaries, 
androgens, and insulin (Fig. 1). An important ele-
ment of this syndrome is insulin resistance. The 
majority of women with the polycystic ovary syn-
drome, regardless of weight, have a form of insu-
lin resistance that is intrinsic to the syndrome and 
is poorly understood.9‑11 Obese women with the 
polycystic ovary syndrome have an added burden 
of insulin resistance related to their adiposity.11
The insulin resistance that is characteristic of 
the polycystic ovary syndrome appears to be re-
sponsible for the association of the disorder with 
type 2 diabetes.12 Insulin resistance may also 
underlie the association of the polycystic ovary 
syndrome with recognized cardiovascular risk fac-
tors such as dyslipidemia and hypertension,13 as 
well as with anatomical14‑17 and functional16,18,19 
cardiovascular derangements.
Insulin resistance and compensatory hyperin-
sulinemia also play an important role in other 
aspects of the polycystic ovary syndrome, includ-
ing androgen excess and anovulation (Fig. 1). In-
sulin stimulates the ovarian production of an-
drogen by activating its homologous receptor,20,21 
and the ovaries of women with the polycystic 
ovary syndrome appear to remain sensitive to in-
sulin,22 or perhaps hypersensitive to it,23‑25 even 
when classic target tissues such as muscle and 
fat manifest resistance to insulin action. In ad-
dition, hyperinsulinemia inhibits the hepatic pro-
duction of sex hormone–binding globulin,26 fur-
ther increasing circulating free testosterone levels. 
Finally, insulin impedes ovulation, either by di-
rectly affecting follicular development or by in-
directly increasing intraovarian androgen levels 
or altering gonadotropin secretion.27 Further evi-
dence of the influence of insulin resistance in 
the polycystic ovary syndrome is that multiple 
diverse interventions, which are related to one 
another only in that they lower circulating insu-
lin levels, result in increased frequency of ovula-
tion or menses, reduced serum testosterone lev-
els, or both. These interventions include the 
inhibition of insulin release (with the use of di-
azoxide20 or octreotide28), improvement of insu-
lin sensitivity (with the use of diet-induced weight 
loss,29 metformin,30,31 troglitazone,32 rosiglita-
zone,23,33 or pioglitazone34), or the reduction of 
carbohydrate absorption (with the use of acar-
bose35).
Metformin, a biguanide, is the most widely 
used drug for the treatment of type 2 diabetes 
worldwide. Its primary action is to inhibit he-
patic glucose production, but it also increases 
the sensitivity of peripheral tissues to insulin.36 
The increase in insulin sensitivity, which contrib-
utes to the efficacy of metformin in the treat-
ment of diabetes, has also been shown in nondia-
betic women with the polycystic ovary syndrome.37 
In women with the syndrome, long-term treat-
ment with metformin may increase ovulation, 
improve menstrual cyclicity, and reduce serum 
androgen levels30,31; the use of metformin may 
also improve hirsutism.38 If published data on 
the effects of metformin in the prevention of dia-
betes can be extrapolated to women with the 
polycystic ovary syndrome, then the drug may 
actually retard progression to glucose intolerance 
in affected women, as reported in a small, retro-
spective study.39
Cl inic a l E v idence
In 1996, it was reported that the administration 
of metformin to women with the polycystic ovary 
syndrome reduced circulating insulin levels and 
was associated with decreases in ovarian 17,20-
lyase activity and ovarian secretion of andro-
gens.40 Most, but not all, subsequent studies con-
firmed the ability of metformin to lower fasting 
serum insulin30 and androgen31 levels in women 
with the polycystic ovary syndrome. However, 
studies specifically assessing the effects of met-
formin on clinical signs of androgen excess (e.g., 
hirsutism, acne, and androgenetic alopecia) are 
limited.38
With regard to ovulation, in results of a ran-
domized clinical trial reported in 1998, pretreat-
ment with metformin, as compared with placebo, 
increased the incidence of ovulation after subse-
quent treatment with clomiphene.41 Subsequent-
ly, several studies compared metformin with pla-
cebo, metformin with no treatment, metformin 
plus clomiphene with clomiphene alone, or met-
formin plus clomiphene with placebo. The most 
rigorous of these studies were included in a 
meta-analysis by Lord et al. in 2003.30 The meta-
analysis included data from 13 trials and 543 
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women with the polycystic ovary syndrome; it was 
concluded that metformin is effective in increas-
ing the frequency of ovulation (odds ratio, 3.88; 
95% confidence interval, 2.25 to 6.69).
Since publication of the meta-analysis, three 
additional randomized clinical trials have been 
published.42‑44 They involved head-to-head com-
parisons of metformin or metformin plus clomi-
phene with clomiphene for the short-term induc-
tion of ovulation in women with the polycystic 
ovary syndrome who desire pregnancy, and the 
trials yielded conflicting results. The largest of 
these trials, the Pregnancy in Polycystic Ovary 
Syndrome trial,42 included 626 infertile women 
with the polycystic ovary syndrome. It confirmed 
that the addition of metformin to clomiphene 
therapy increased the cumulative ovulation rate 
as compared with administration of clomiphene 
alone (60.4% vs. 49.0%, P = 0.003), but the rate of 
live birth did not differ between the two groups 
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Figure 1. Pathophysiological Characteristics of the Polycystic Ovary Syndrome (PCOS).
Insulin resistance results in a compensatory hyperinsulinemia, which stimulates ovarian androgen production in an 
ovary genetically predisposed to PCOS. Arrest of follicular development (red “X”) and anovulation could be caused 
by the abnormal secretion of gonadotropins such as follicle-stimulating hormone (FSH) or luteinizing hormone (LH) 
(perhaps induced by hyperinsulinemia), intraovarian androgen excess, direct effects of insulin, or a combination of 
these factors. Insulin resistance, in concert with genetic factors, may also lead to hyperglycemia and an adverse 
profile of cardiovascular risk factors. PAI-1 denotes plasminogen-activator inhibitor type 1.
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(26.8% and 22.5%, respectively; P = 0.31). In that 
study, clomiphene was more effective than met-
formin in inducing ovulation in the short term 
and producing a live birth.
With regard to diabetes, two major random-
ized clinical trials, the Indian Diabetes Preven-
tion Programme (IDPP-1)45 and the U.S. Diabe-
tes Prevention Program (DPP),46 have shown that 
the use of metformin decreases the relative risk 
for progression to type 2 diabetes (by 26% and 
31%, respectively) among patients with impaired 
glucose tolerance at baseline. Whether this effect 
of metformin truly represented the prevention of 
progression to diabetes, rather than simply the 
masking of progression by means of lowering 
blood glucose levels, remains controversial. How-
ever, after the discontinuation of metformin in 
the DPP, diabetes developed in fewer subjects 
than would have been expected if masking had 
been the sole effect.47 To my knowledge, no ran-
domized clinical trial has assessed the effect of 
metformin on the progression to type 2 diabetes 
specifically in patients with the polycystic ovary 
syndrome. In an uncontrolled, retrospective study 
of 50 women with the polycystic ovary syndrome 
treated with metformin for an average of 43 
months at an academic medical center, there was 
no progression to type 2 diabetes, even though 
11 women (22.0%) had impaired glucose toler-
ance at baseline.39 The annual conversion rate 
from normal glucose tolerance to impaired glu-
cose tolerance was only 1.4%, as compared with 
16 to 19% reported in the literature4,6 for women 
with the polycystic ovary syndrome who are not 
taking metformin.
Cl inic a l Use
The approach to the management of the polycystic 
ovary syndrome depends in part on the patient’s 
and physician’s principal therapeutic objectives. 
For some women, infertility is the principal issue. 
Such patients are frequently treated in the short 
term with clomiphene, to induce ovulation. When 
fertility is not a concern, an estrogen–progestin 
contraceptive, with or without an antiandrogen 
such as spironolactone, has been the mainstay of 
long-term therapy. This approach is effective in 
achieving the traditional treatment goals in the 
polycystic ovary syndrome, which include ame-
liorating the effects of androgen excess (e.g., hir-
sutism, male pattern baldness, and acne) and 
restoring regular menses, thereby preventing endo-
metrial hyperplasia.
However, given the metabolic derangements 
associated with the polycystic ovary syndrome, it 
seems prudent and appropriate to plan long-term 
therapy that addresses not only management of 
the consequences of androgen excess and anovu-
lation but also the new goals of ameliorating in-
sulin resistance and reducing the risks of type 2 
diabetes and cardiovascular disease. The effect of 
estrogen–progestin contraceptive agents on glu-
cose tolerance is controversial. Limited evidence 
from controlled, short-term studies suggests that 
the use of oral contraceptives aggravates insulin 
resistance and worsens glucose tolerance in wom-
en with the polycystic ovary syndrome.48 The use 
of estrogen–progestin contraceptives is associat-
ed with a twofold increase in the relative risk of 
cardiovascular arterial events in the general fe-
male population49; the risk among women with 
the polycystic ovary syndrome in particular is 
unknown.
Metformin improves insulin sensitivity and, 
as noted earlier, has been shown to retard or 
prevent progression to type 2 diabetes in patients 
with impaired glucose tolerance. Although met-
formin has not been specifically shown to reduce 
the risk of cardiovascular events in patients with 
the polycystic ovary syndrome, the available mech-
anistic and clinical evidence support the use of 
metformin as a protective measure against the 
adverse cardiovascular effects of insulin resis-
tance and insulin excess. In addition, metformin 
may decrease circulating androgen levels and may 
improve ovulation and menstrual cyclicity, thus 
addressing the traditional goals of long-term 
treatment. For these reasons, although metfor-
min is not approved by the Food and Drug Ad-
ministration for the treatment of the polycystic 
ovary syndrome, the drug is commonly used for 
this purpose.
To minimize side effects, metformin therapy 
is initiated at a low dose taken with meals, and 
the dose is then progressively increased. My prac-
tice is to have patients take 500 mg of metformin 
once daily with the largest meal, usually dinner, 
for 1 week; then increase the dose to 500 mg 
twice daily, with breakfast and dinner, for 1 week; 
increase the dose to 500 mg with breakfast and 
1000 mg with dinner, for 1 week; and finally, 
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increase the dose to 1000 mg twice daily, with 
breakfast and dinner. There is no dose-ranging 
study of metformin in the polycystic ovary syn-
drome, but a dose-ranging study of patients with 
diabetes, using the glycated hemoglobin level as 
the outcome measure, suggested that a dose of 
2000 mg daily is optimal.50
Metformin should not be used in women 
with renal impairment (a serum creatinine level 
>1.4 mg per deciliter [124 μmol per liter]), he-
patic dysfunction, severe congestive heart failure, 
or a history of alcohol abuse. Given the young 
age of women with the polycystic ovary syn-
drome, these contraindications are rarely an issue. 
Repeat testing during metformin treatment is not 
indicated unless an illness or condition (e.g., de-
hydration) that might affect renal or hepatic func-
tion develops.
When metformin is prescribed, advice about a 
weight-loss diet and a scheduled exercise routine 
should also be given. Such interventions are 
beneficial in preventing diabetes.45,46 In addition, 
weight loss increases the likelihood of resuming 
ovulation, most likely as a result of improved 
insulin sensitivity.29,51
The patient is asked to maintain a menstrual 
diary, cautioned that fertility may be rapidly es-
tablished, and advised to use a barrier method 
of contraception. Oral contraceptive agents and 
antiandrogens are not administered at the initial 
visit, since they might affect menstruation or 
serum androgen levels and confound the assess-
ment of the efficacy of metformin. Topical eflor-
nithine can be prescribed for the treatment of 
facial hirsutism.
Follow-up visits are scheduled at 3 and 
6 months. Menstrual cyclicity is reviewed and 
serum total testosterone is determined at each 
visit. If an improvement in menstrual cyclicity is 
noted, it is important to document whether the 
menses are ovulatory. This can be accomplished 
by measuring the serum progesterone level 7 days 
before the next onset of menses; a serum pro-
gesterone level of more than 4.0 ng per milliliter 
(12.7 nmol per liter) is consistent with the pres-
ence of the luteal phase and ovulation.
After 6 to 9 months of treatment, the efficacy 
of metformin is assessed. If menstrual cyclicity 
and ovulation are satisfactorily improved, further 
treatment is individualized. For some women, 
treatment with metformin alone might suffice. 
Women desiring contraception could be given an 
oral contraceptive agent while continuing to take 
metformin. In cases in which hirsutism remains 
troublesome, an oral contraceptive agent, anti-
androgen, or both could be added to metformin.
A dv er se Effec t s
Lactic acidosis has been reported with the use of 
metformin, but this complication is rare (0.3 epi-
sode per 10,000 patient-years) in otherwise healthy 
patients and is confined primarily to patients who 
should not have received the drug, because they had 
underlying renal or hepatic disease.
The main limiting side effect of metformin, 
affecting 10 to 25% of patients, is gastrointesti-
nal distress, namely nausea and diarrhea. If the 
nausea or diarrhea occurs at a given dose, that 
dose is either maintained or decreased by 500 mg 
per day for 2 to 4 weeks until the symptoms 
abate. Fortunately, the gastrointestinal side ef-
fects of metformin are usually transient; however, 
in a minority of cases, gastrointestinal distress 
may require the discontinuation of metformin.
Metformin can cause malabsorption of vitamin 
B12 in some patients receiving long-term therapy. 
In one analysis, risk factors for the development 
of this adverse effect included both the daily dose 
and duration of metformin therapy as well as 
age.52 Although the likelihood of clinical defi-
ciency of vitamin B12 appears to be low, patients 
should be monitored for signs and symptoms.
Metformin is a category B drug, and no tera-
togenic effects have been found in animal mod-
els. It was administered in South Africa to a 
limited number of women with type 2 diabetes 
or gestational diabetes, throughout their preg-
nancies, and no teratogenic effects or adverse 
fetal outcomes were reported.31
A r e a s of Uncerta in t y
Although metformin is increasingly used to treat 
patients with the polycystic ovary syndrome, ther-
apy is guided in part by the results of random-
ized, controlled trials in populations without the 
polycystic ovary syndrome, which showed that 
diabetes was prevented. Similar randomized, con-
trolled trials specifically involving patients with 
the polycystic ovary syndrome are needed. Strate-
gies for long-term metformin therapy in patients 
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with the polycystic ovary syndrome are evolving, 
and the identification of predictors of the re-
sponse to metformin, possibly even through phar-
macogenomic approaches, would improve the 
utility of this agent in the management of the 
polycystic ovary syndrome. Although long-term 
treatment with metformin seems likely to be ben-
eficial in many patients with the polycystic ovary 
syndrome, less clear is when metformin should be 
used as monotherapy or in combination with anti-
androgens or hormonal therapies. The efficacy of 
metformin in ameliorating the signs of androgen 
excess, such as hirsutism, has not been critically 
assessed.
Metformin has been used for many years in 
patients with type 2 diabetes. However, we do 
not have data regarding the potential long-term 
effects of the drug in patients treated for the 
polycystic ovary syndrome, in whom therapy, if 
effective, may be continued for many years. If a 
woman were to become pregnant, it is unclear 
whether metformin should be continued during 
pregnancy and, if so, for how long.
Guidel ines
The recent position statement of the Androgen 
Excess Society53 recommends that women with 
the polycystic ovary syndrome, regardless of 
weight, be screened for glucose intolerance with 
the use of a glucose-tolerance test at the initial 
presentation and every 2 years thereafter. It notes 
that the use of metformin to treat or prevent 
progression to impaired glucose tolerance may 
be considered but should not be mandated until 
there have been well-designed randomized, con-
trolled trials demonstrating efficacy. A position 
statement of the American Association of Clin-
ical Endocrinologists54 recommends that met-
formin be considered the initial intervention 
in most women with the polycystic ovary syn-
drome, particularly those who are overweight or 
obese.
R ecommendations
The obesity, family history of diabetes, and poly-
cystic ovary syndrome of the patient in the vignette 
put her at high risk for type 2 diabetes. In addi-
tion to obesity, she has several signs of insulin 
resistance, including a low serum high-density 
lipoprotein cholesterol level and a high triglycer-
ide level, and her data fulfill the Adult Treatment 
Panel III criteria of the National Cholesterol Edu-
cation Program for the metabolic syndrome.55,56 
Although her glucose tolerance is currently nor-
mal, treatment with metformin is reasonable, 
and a weight-loss diet and exercise are also en-
couraged.
Although fertility is not an immediate con-
cern, it is likely that metformin will increase the 
frequency of ovulation, thereby improving men-
strual cyclicity. Once menstrual cyclicity has im-
proved, I would determine whether ovulation is 
occurring by measuring the serum progesterone 
level during the presumed luteal phase. Since the 
patient does not tolerate oral contraceptives, a 
barrier method of contraception could be recom-
mended. When and if the patient desires preg-
nancy, fertility may be improved if the frequency 
of ovulation increases during metformin therapy. 
If not, the patient should be evaluated for causes 
of infertility unrelated to anovulation, and the 
addition of clomiphene to her regimen should be 
discussed.
I would see the patient every 3 months during 
the first year, not only to monitor the efficacy of 
metformin but also to reinforce lifestyle changes 
to reduce weight and increase physical activity. 
Thereafter, she could be seen every 6 to 12 months, 
depending on the response to treatment. Given 
that she is at high risk for diabetes, I would repeat 
the oral glucose-tolerance test every 2 to 3 years, 
even if metformin therapy is used.
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